Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Fosamprenavir Calcium

FDA-approved product (tablet, oral), marketed as Fosamprenavir Calcium, Lexiva.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Fosamprenavir Calcium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • Immunodeficiency disease
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Protease inhibitors
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AE05; WHO ATC J05AE07

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA43.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli39.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae22.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis62.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Fosamprenavir Calcium in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Fosamprenavir Calcium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study To Assess GW433908 (Fosamprenavir) Containing Regimens In HIV-1 Infected Subjects

    NCT00296504 · start 2001-11

    Registered record
    Registry ID
    NCT00296504
    Conditions
    Infection, Human Immunodeficiency Virus
    Interventions
    fosamprenavir (GW433908); ritonavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-11
    Completion
    2010-10
    Enrolment
    753

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection, Human Immunodeficiency Virus
    Interventionfosamprenavir (GW433908); ritonavir
    PhasePhase 3
    Registry statusCompleted

  • Comparison of Two Dosing Regimens of GW433908/Ritonavir Versus Lopinavir/Ritonavir for 48 Weeks in HIV Patients Who Have Taken Protease Inhibitors and Experienced Virological Failure

    NCT00025727 · start 2001-05

    Registered record
    Registry ID
    NCT00025727
    Conditions
    HIV Infections
    Interventions
    Lopinavir/Ritonavir; Ritonavir; GW433908
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2001-05
    Completion
    Not recorded
    Enrolment
    330

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionLopinavir/Ritonavir; Ritonavir; GW433908
    PhasePhase 3
    Registry statusUnknown

  • Comparison of GW433908/Ritonavir to Nelfinavir When Used With Abacavir and Lamivudine in Patients That Have Not Taken Antiretroviral Drugs

    NCT00009061 · start 2000-11

    Registered record
    Registry ID
    NCT00009061
    Conditions
    HIV Infections
    Interventions
    Ritonavir; Abacavir sulfate; Nelfinavir mesylate; Lamivudine; GW433908
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2000-11
    Completion
    Not recorded
    Enrolment
    624

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionRitonavir; Abacavir sulfate; Nelfinavir mesylate; Lamivudine +1 more
    PhasePhase 3
    Registry statusUnknown

  • Using Drug Levels and Drug Resistance Testing to Select Effective Anti-HIV Drug Combinations in Patients With Drug-resistant HIV

    NCT00027339

    Registered record
    Registry ID
    NCT00027339
    Conditions
    HIV Infections
    Interventions
    lopinavir/ritonavir; indinavir sulfate; tenofovir disoproxil fumarate; ritonavir; fosamprenavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    Not recorded
    Completion
    2005-06
    Enrolment
    53

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    Interventionlopinavir/ritonavir; indinavir sulfate; tenofovir disoproxil fumarate; ritonavir +1 more
    PhasePhase 2
    Registry statusCompleted

  • Dual Versus Triple Protease Inhibitor Combinations, Including Ritonavir, in HIV Infected People

    NCT00028366

    Registered record
    Registry ID
    NCT00028366
    Conditions
    HIV Infections
    Interventions
    Fosamprenavir; Lopinavir/Ritonavir; Ritonavir; Tenofovir disoproxil fumarate
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    Not recorded
    Completion
    2005-07
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionFosamprenavir; Lopinavir/Ritonavir; Ritonavir; Tenofovir disoproxil fumarate
    PhaseNot applicable
    Registry statusCompleted